RECRUITING

Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE

Talk to us

Conditions

Uterine Fibroid

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study goals are to determine the patterns of uterine fibroid vascularity pre and post UAE using CEUS resulting in an alternative to gadolinium-enhanced MRI that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the result of UAE procedures. Also, this study will evaluate uterine fibroid pressures using SHAPE, comparing the results with normal myometrium tissue in order to determine its characteristics and tissue differences, which we believe will lead to the development of a new biomarker for the diagnosis and treatment of uterine fibroids.

Official Title

Evaluation of Uterine Fibroids by Contrast Enhanced Ultrasound (CEUS) and Subharmonic- Aided Pressure Estimation (SHAPE) Pre and Post-Uterine Artery Embolization (UAE)

Quick Facts

Study Start:2025-01-27
Study Completion:2026-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06705075

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Be a female diagnosed with endometrial cancer and scheduled for UAE.
  2. * Be over the age of 18 years.
  3. * If the subject is of child-bearing potential, must have a negative pregnancy test.
  4. * Be conscious and able to comply with study procedures.
  5. * Have read and signed the IRB approved consent form for participating in the study.
  1. * Females who are pregnant or nursing.
  2. * Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards.
  3. * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:
  4. * Patients on life support or in a critical care unit.
  5. * Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia.
  6. * Patients with recent cerebral hemorrhage.
  7. * Patients who have undergone surgery within 24 hours prior to the study sonographic examination.
  8. * Patients with congenital heart defects.
  9. * Patient with a known allergy to Definity.

Contacts and Locations

Study Contact

Priscilla Machado, MD
CONTACT
215-955-4279
priscilla.machado@jefferson.edu

Study Locations (Sites)

Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
United States

Collaborators and Investigators

Sponsor: Thomas Jefferson University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-27
Study Completion Date2026-09-30

Study Record Updates

Study Start Date2025-01-27
Study Completion Date2026-09-30

Terms related to this study

Additional Relevant MeSH Terms

  • Uterine Fibroid